Allurion stock surged more than 50% following FDA premarket approval for its swallowable Gastric Balloon System. The non-surgical Smart Capsule helps patients feel fuller for months without anesthesia. The company positions the device as a safe, effective alternative to GLP-1 medications, paving the way for its expansion across the United States.